

# David Chandler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3329161/publications.pdf>

Version: 2024-02-01

7  
papers

102  
citations

1478458

6  
h-index

1720014

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

111  
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. <i>Journal of Medical Economics</i> , 2020, 23, 184-192.	2.1	29
2	Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. <i>Current Medical Research and Opinion</i> , 2017, 33, 2107-2113.	1.9	22
3	Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment. <i>Current Medical Research and Opinion</i> , 2019, 35, 1073-1080.	1.9	15
4	Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice: a retrospective observational study. <i>BMC Cancer</i> , 2019, 19, 792.	2.6	14
5	Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims. <i>Current Medical Research and Opinion</i> , 2018, 34, 1705-1711.	1.9	11
6	Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015. <i>Current Medical Research and Opinion</i> , 2017, 33, 2115-2120.	1.9	8
7	Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims. <i>Current Medical Research and Opinion</i> , 2019, 35, 725-730.	1.9	3